Abstract
The introduction, more than half a century ago, of the randomized trial in which allocation to the experimental and control interventions occurs by chance has been a pivotal point in the evaluation of therapeutic efficacy. It is now well accepted that the gold standard in such evaluation is the well‐designed controlled, clinical experiment that has high methodological rigour so that bias can be minimized and the magnitude of treatment effect can be estimated reliably and confidently. The acceptance of the randomized controlled trial (RCT) in the field of reproductive medicine is evident by the increasing numbers of such trials being published.

This publication has 0 references indexed in Scilit: